Glaucoma is a number one trigger of irreversible blindness. Remodeling of the scleral extracellular matrix (ECM) performs an vital position in the event of glaucoma. The goal of this research was to determine the key genes and pathways for the ECM remodeling of sclera in glaucoma by bioinformatics analysis and to discover potential therapeutic agents for glaucoma administration. Genes related to glaucoma, sclera and ECM remodeling have been detected using the textual content mining software pubmed2ensembl, and assigned Gene Ontology (GO) organic course of phrases and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using the GeneCodis program.
A protein-protein interplay (PPI) community was constructed by STRING and visualized in Cytoscape, module analysis was carried out using the Molecular Complex Detection (MCODE) plugin, and GO and KEGG analyses of the gene modules have been carried out using the Database of Annotation, Visualization and Integrated Discovery (DAVID) platform. The genes that clustered in the numerous module have been chosen as core genes, and features and pathways of the core genes have been visualized using ClueGO and CluePedia. Lastly, the drug-gene interplay database was used to discover drug-gene interactions of the core genes to seek out drug candidates for glaucoma.
We recognized 125 genes widespread to “Glaucoma”, “Sclera”, and “ECM remodeling” by textual content mining. Gene useful enrichment analysis yielded 30 enriched GO phrases and 20 related KEGG pathways. A PPI community that included 60 nodes with 249 edges was constructed, and three gene modules have been obtained using the MCODE. We chosen 13 genes that clustered in module 1 as core candidate genes that have been related primarily with ECM degradation and cell proliferation and division.
The HIF-1 signaling pathway, FOXO signaling pathway, PI3K-Akt signaling pathway and TGFB signaling pathway have been discovered to be enriched. We discovered that 11 of the 13 chosen genes might be focused by 26 present medicine. The outcomes confirmed that VEGFA, TGFB1, TGFB2, TGFB3, IGF2, IGF1, EGF, FN1, KNG1, TIMP1, SERPINE1, THBS1, and VWF have been potential key genes concerned to scleral ECM remodeling. Furthermore, 26 medicine have been recognized as potential therapeutic agents for glaucoma remedy and administration.
STATegra: Multi-Omics Data Integration – A Conceptual Scheme With a Bioinformatics Pipeline
Technologies for profiling samples using completely different omics platforms have been on the forefront for the reason that human genome venture. Large-scale multi-omics information maintain the promise of deciphering completely different regulatory layers. Yet, whereas there’s a myriad of bioinformatics instruments, every multi-omics analysis seems to begin from scratch with an arbitrary resolution over which instruments to make use of and the way to mix them. Therefore, it’s an unmet must conceptualize the way to combine such information and implement and validate pipelines in completely different circumstances.
We have designed a conceptual framework (STATegra), aiming it to be as generic as potential for multi-omics analysis, combining accessible multi-omic anlaysis instruments (machine studying element analysis, non-parametric information mixture, and a multi-omics exploratory analysis) in a step-wise method. While in a number of research, we’ve got beforehand mixed these integrative instruments, right here, we offer a scientific description of the STATegra framework and its validation using two The Cancer Genome Atlas (TCGA) case research. For each, the Glioblastoma and the Skin Cutaneous Melanoma (SKCM) circumstances, we reveal an enhanced capability of the framework (and past the person instruments) to determine options and pathways in comparison with single-omics analysis.
Such an integrative multi-omics analysis framework for figuring out options and elements facilitates the invention of new biology. Finally, we offer a number of choices for making use of the STATegra framework when parametric assumptions are fulfilled and for the case when not all of the samples are profiled for all omics. The STATegra framework is constructed using a number of instruments, that are being built-in step-by-step as OpenSource in the STATegRa Bioconductor package deal.
Identification of Pivotal MicroRNAs and Target Genes Associated with Persistent Atrial Fibrillation Based on Bioinformatics Analysis
Atrial fibrillation (AF) is one of the most typical supraventricular arrhythmias worldwide. However, the particular molecular mechanism underlying AF stays unclear. Our research is geared toward figuring out pivotal microRNAs (miRNAs) and concentrating on genes related to persistent AF (pAF) using bioinformatics analysis. Three gene expression array datasets and an miRNA expression array dataset (GSE68475) related to pAF have been downloaded. Differentially expressed genes (DEGs) have been recognized using the LIMMA package deal, and differentially expressed miRNAs (DEMs) have been screened from GSE68475.
Target genes for DEMs have been predicted using the miRTarBase database, and intersections between these goal genes and DEGs have been chosen for additional analysis, together with the technology of protein-protein interplay (PPI) community, miRNA-transcription factor-target regulatory community, and drug-gene community. A complete of 264 DEGs and 40 DEMs have been recognized between the pAF and management teams. Functional and pathway enrichment analyses of up- and downregulated DEGs have been carried out. The widespread genes (CGs) have been primarily enriched in the phosphoinositide 3-kinase- (PI3K-) protein kinase B (Akt) signaling pathway, unfavourable regulation of cell division, and response to hypoxia.
 Bead Sample Pack - Microcentrifuge Set |
|
BSP-MC2 |
Next Advance |
1pack |
EUR 278.4 |
|
Description: Bead sample pack for Bullet Blender 1.5mL tube models. Includes 10mL of: ZROB015, ZROB05, ZROB10, ZROB20, SSB02, SSB14B, SSB32 and SSUFO35. |
 All Sample Diluents Sample Pack |
|
KF17355 |
Neuromics |
3X100 ml |
EUR 326.4 |
 3 Blocking Buffer Sample Pack |
|
KF17340 |
Neuromics |
3 x 100 ml |
EUR 246 |
 All Assay Diluents Sample Pack |
|
KF17351 |
Neuromics |
4X100 ml |
EUR 326.4 |
 Plastic Forceps for Manipulating Tissue Samples 6 pcs/pack |
|
IW-2310 |
IHC World |
6 pcs/pack |
EUR 9.99 |
 Anti Human Plasminogen MAb Sample Pack |
|
MBS480366-1Pack |
MyBiosource |
1Pack |
EUR 825 |
Anti Human Plasminogen MAb Sample Pack |
|
MBS480366-5x1Pack |
MyBiosource |
5x1Pack |
EUR 3490 |
 Soft Tissue Tissue Slide |
|
MBS154324-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide |
|
MBS154324-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide |
|
MBS154324-5x10um |
MyBiosource |
5x10um |
EUR 920 |
 Sample Diluent Optimization Pack: 100mL SD1, SD2, SD3, PFSD |
|
959 |
Immunochemistry |
pack |
EUR 187 |
 Sample Diluent Optimization Pack: All Three 100mL SDs |
|
MBS258064-1Pack |
MyBiosource |
1Pack |
EUR 265 |
Sample Diluent Optimization Pack: All Three 100mL SDs |
|
MBS258064-5Packs |
MyBiosource |
5Packs |
EUR 1010 |
 Soft tissue tumor tissue array |
|
BC24011b |
TissueArray |
each |
EUR 270 |
|
Description: Soft tissue tumor tissue array, including TNM and clinical stage, 63 cases/63 cores, replacing BC24011a |
Soft tissue tumor tissue array |
|
SF961 |
TissueArray |
each |
EUR 222 |
|
Description: Soft tissue tumor tissue array, including TNM and clinical stage, 48 cases/96 cores |
) Soft Tissue Tissue Slide (Benign) |
|
12-303-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Benign) |
|
12-303-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Benign) |
|
MBS154245-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Benign) |
|
MBS154245-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Benign) |
|
MBS154245-5x10um |
MyBiosource |
5x10um |
EUR 920 |
) Soft Tissue Tissue Slide (Abnormal) |
|
12-305-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Abnormal) |
|
12-305-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Abnormal) |
|
MBS154256-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Abnormal) |
|
MBS154256-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Abnormal) |
|
MBS154256-5x10um |
MyBiosource |
5x10um |
EUR 920 |
HumanSoft tissuesMulti-organsMalignant) Tumors of soft tissue, 102 cases (1.5mm)HumanSoft tissuesMulti-organsMalignant |
|
SFT1021 |
Pantomics |
1 |
EUR 289 |
 Soft tissue cancer test tissue array |
|
T241 |
TissueArray |
each |
EUR 48 |
|
Description: Soft tissue cancer test tissue array, with normal soft tissue control tissue, including TNM, clinical stage and pathology grade, 6 cases/24 cores |
 Soft tissue sarcoma test tissue array |
|
T243 |
TissueArray |
each |
EUR 66 |
|
Description: Soft tissue sarcoma test tissue array, with normal soft tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases/24 cores (core size 1.5mm) |
Soft tissue sarcoma test tissue array |
|
T243a |
TissueArray |
each |
EUR 66 |
|
Description: Soft tissue sarcoma test tissue array,with normal soft tissue as control,TNM/Stage ( AJCC 8th edition), 6 cases/24 cores(corse size 1.5mm) |
, set 1HumanSoft tissuesMulti-organsMalignant) Tumors of soft tissue, 48 cases (1.5mm), set 1HumanSoft tissuesMulti-organsMalignant |
|
SFT961 |
Pantomics |
1 |
EUR 289 |
 Soft tissue malignant tumor tissue array |
|
T244 |
TissueArray |
each |
EUR 48 |
|
Description: Soft tissue malignant tumor tissue array, including TNM and clinical stage, 6 cases/24 cores |
) Soft Tissue Tissue Slide (Adipose-Normal) |
|
12-311-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Adipose-Normal) |
|
12-311-4um |
ProSci |
4 um |
EUR 216.6 |
) Soft Tissue Tissue Slide (Adipose-Benign) |
|
12-313-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Adipose-Benign) |
|
12-313-4um |
ProSci |
4 um |
EUR 216.6 |
) Soft Tissue Tissue Slide (Adipose-Lipoma) |
|
12-314-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Adipose-Lipoma) |
|
12-314-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Adipose-Lipoma) |
|
MBS154181-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Adipose-Lipoma) |
|
MBS154181-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Adipose-Lipoma) |
|
MBS154181-5x10um |
MyBiosource |
5x10um |
EUR 920 |
Soft Tissue Tissue Slide (Adipose-Benign) |
|
MBS154250-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Adipose-Benign) |
|
MBS154250-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Adipose-Benign) |
|
MBS154250-5x10um |
MyBiosource |
5x10um |
EUR 920 |
Soft Tissue Tissue Slide (Adipose-Normal) |
|
MBS154286-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Adipose-Normal) |
|
MBS154286-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Adipose-Normal) |
|
MBS154286-5x10um |
MyBiosource |
5x10um |
EUR 920 |
) Soft Tissue Tissue Slide (Adipose-Abnormal) |
|
12-317-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Adipose-Abnormal) |
|
12-317-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Adipose-Abnormal) |
|
MBS154243-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Adipose-Abnormal) |
|
MBS154243-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Adipose-Abnormal) |
|
MBS154243-5x10um |
MyBiosource |
5x10um |
EUR 920 |
 Soft tissue sarcoma as control |
|
SO809c |
TissueArray |
each |
EUR 270 |
|
Description: Soft tissue sarcoma as control, including TNM, clinical stage and pathology grade, 80 cases/80 cores (core size 1.5mm), replacing SO809b |
) Soft Tissue Tissue Slide (Adipose-Undiagnosed) |
|
12-310-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Adipose-Undiagnosed) |
|
12-310-4um |
ProSci |
4 um |
EUR 216.6 |
) Soft Tissue Tissue Slide (Adipose-Liposarcoma) |
|
12-316-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Adipose-Liposarcoma) |
|
12-316-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Adipose-Liposarcoma) |
|
MBS154308-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Adipose-Liposarcoma) |
|
MBS154308-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Adipose-Liposarcoma) |
|
MBS154308-5x10um |
MyBiosource |
5x10um |
EUR 920 |
 Soft tissue tumor with normal tissue array |
|
SO801a |
TissueArray |
each |
EUR 306 |
|
Description: Soft tissue tumor with normal tissue array, including TNM and clinical stage, 80 cases/80 cores, replaced by SO801b |
 Soft tissue tumor array with autopsy tissue |
|
T242b |
TissueArray |
each |
EUR 66 |
|
Description: Soft tissue tumor array with autopsy tissue, including TNM, clinical stage, 12 cases/ 24 cores, replacing T242a |
) Soft Tissue Tissue Slide (Skeletal Muscle-Normal) |
|
12-341-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Skeletal Muscle-Normal) |
|
12-341-4um |
ProSci |
4 um |
EUR 216.6 |
) Soft Tissue Tissue Slide (Skeletal Muscle-Benign) |
|
12-343-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Skeletal Muscle-Benign) |
|
12-343-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Skeletal Muscle-Normal) |
|
MBS154227-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Skeletal Muscle-Normal) |
|
MBS154227-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Skeletal Muscle-Normal) |
|
MBS154227-5x10um |
MyBiosource |
5x10um |
EUR 920 |
Soft Tissue Tissue Slide (Skeletal Muscle-Benign) |
|
MBS154290-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Skeletal Muscle-Benign) |
|
MBS154290-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Skeletal Muscle-Benign) |
|
MBS154290-5x10um |
MyBiosource |
5x10um |
EUR 920 |
) Fixed Tissue Protein Extraction Kit (suitable for animal tissue sample) |
|
EX2171 |
Solarbio Life Science |
-
Ask for price
-
Ask for price
|
|
) Soft Tissue Tissue Slide (Skeletal Muscle-malignant) |
|
12-345-10um |
ProSci |
10 um |
EUR 241.8 |
Soft Tissue Tissue Slide (Skeletal Muscle-malignant) |
|
12-345-4um |
ProSci |
4 um |
EUR 216.6 |
Soft Tissue Tissue Slide (Skeletal Muscle-malignant) |
|
MBS154272-10um |
MyBiosource |
10um |
EUR 210 |
Soft Tissue Tissue Slide (Skeletal Muscle-malignant) |
|
MBS154272-4um |
MyBiosource |
4um |
EUR 195 |
Soft Tissue Tissue Slide (Skeletal Muscle-malignant) |
|
MBS154272-5x10um |
MyBiosource |
5x10um |
EUR 920 |
) Tumors of soft tissue, 75 cases (1.1mm) |
|
SFT1501 |
Pantomics |
1 |
EUR 300 |
|
Description: Soft tissue tumor tissue array, 150 cores, 75 cases of benign and malignant tumors of various soft tissues in duplicates. |
 Soft tissue tumor with adjacent normal tissue array |
|
SO241 |
TissueArray |
each |
EUR 66 |
|
Description: Soft tissue tumor with adjacent normal tissue array, including TNM and clinical stage, 12 cases/24 cores |
) Protein A Tell-Tale Gold® Ribbon Sample Pack, 3 x (1 cm x 30 cm) |
|
TTGA-SP3-B090 |
BioAssayWorks |
3 x (1 cm x 30 cm) |
EUR 208.7 |
) Protein G Tell-Tale Gold® Ribbon Sample Pack, 3 x (1 cm x 30 cm) |
|
TTGG-SP3-B090 |
BioAssayWorks |
3 x (1 cm x 30 cm) |
EUR 208.7 |
 Soft tissue tumor tissue array with normal tissue as control |
|
SO481 |
TissueArray |
each |
EUR 198 |
|
Description: Soft tissue tumor tissue array with normal tissue as control, including TNM and clinical stage, 48 cases/48 cores |
) Soft tissue fibrosarcoma tissue array (2013 WHO classification) |
|
SO961 |
TissueArray |
each |
EUR 306 |
|
Description: Soft tissue fibrosarcoma tissue array (2013 WHO classification), including TNM and clinical stage (AJCC 7th edition), 96 cases/96 cores |
 Multiple sarcoma of soft tissue array with normal tissue |
|
SO208a |
TissueArray |
each |
EUR 546 |
|
Description: Multiple sarcoma of soft tissue array with normal tissue, including pathology grade, TNM and clinical stage, 64 cases/192 cores, replacing SO208 |
) Protein A/G Tell-Tale Gold® Ribbon Sample Pack, 3 x (1 cm x 30 cm) |
|
TTGAG-SP3-B090 |
BioAssayWorks |
3 x (1 cm x 30 cm) |
EUR 208.7 |
HumanMulti-systemMulti-organsNormal) Multi-normal human tissues, FDA, 102 samples, 35 organs-sites from three individuals (1.5mm)HumanMulti-systemMulti-organsNormal |
|
MNO1022 |
Pantomics |
1.5mm |
EUR 310 |
 (5 slides/pk)) Human Soft Tissue Slide (Benign) (5 slides/pk) |
|
HTS-12303 |
Alpha Diagnostics |
1 pk |
EUR 343.2 |
) Common diseases of soft tissue, 24 cases (2.5mm) |
|
SFD241 |
Pantomics |
1 |
EUR 228 |
|
Description: Soft tissue disease tissue array, 24 cases of normal, reactive and tumor conditions of various soft tissues |
) Common diseases of soft tissue, 24 cases (2mm) |
|
SFD481 |
Pantomics |
1 |
EUR 265.2 |
|
Description: Soft tissue disease tissue array, 24 cases of reactive and tumor conditions of various soft tissues in duplicates. |
, set 2) Tumors of soft tissue, 48 cases (1.5mm), set 2 |
|
SFT962 |
Pantomics |
1 |
EUR 300 |
|
Description: Soft tissue tumor tissue array, set 2, non-overlapping with SFT961, 96 cores, 48 cases of benign and malignant tumors of various soft tissues in duplicates. |
 (5 slides/pk)) Human Soft Tissue Slide (Abnormal) (5 slides/pk) |
|
HTS-12305 |
Alpha Diagnostics |
1 pk |
EUR 343.2 |
/CD271 (Soft Tissue Tumor Marker)) NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4381113-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4381113-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4381113-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4381113-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4381113-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380135-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380135-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380135-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380135-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380135-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380467-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380467-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380467-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380467-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380467-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380642-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380642-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380642-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380642-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
NGF-Receptor (p75)/CD271 (Soft Tissue Tumor Marker) |
|
MBS4380642-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
 (5 slides/pk)) Human Soft Tissue Slide (Adipose Normal) (5 slides/pk) |
|
HTS-12311 |
Alpha Diagnostics |
1 pk |
EUR 343.2 |
The PPI community, miRNA-transcription factor-target regulatory community, and drug-gene community have been constructed using Cytoscape. The current research revealed a number of novel miRNAs and genes concerned in pAF. We speculated that miR-4298, miR-3125, miR-4306, and miR-671-5p may signify important miRNAs that act on the goal gene superoxide dismutase 2 (SOD2) in the course of the improvement of pAF and might function important biomarkers for pAF analysis and remedy. Moreover, MYC may operate in pAF pathogenesis by means of the PI3K-Akt signaling pathway.
